Get the Stockscreener App
3.455
1.43%
-0.05
After Hours:
3.46
0.005
+0.14%
Polypid Ltd stock is traded at $3.455, with a volume of 19,916.
It is down -1.43% in the last 24 hours and up +4.07% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$3.505
Open:
$3.38
24h Volume:
19,916
Relative Volume:
2.59
Market Cap:
$23.13M
Revenue:
-
Net Income/Loss:
$-23.87M
P/E Ratio:
-0.0952
EPS:
-36.3
Net Cash Flow:
$-47.63M
1W Performance:
-1.00%
1M Performance:
+4.07%
6M Performance:
-25.78%
1Y Performance:
-15.73%
1-Day Range:
$3.31
$3.62
1-Week Range:
$3.30
$3.74
52-Week Range:
$2.95
$9.20
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.455 | 23.13M | 0 | -23.87M | -47.63M | -36.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
PolyPid Ltd. (NASDAQ:PYPD) Q3 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
PolyPid Reports Q3 Results Amid SHIELD II Trial Progress - TipRanks
PolyPid Announces SHIELD II Trial Progress and Financials - TipRanks
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
PolyPid (PYPD) to Release Earnings on Wednesday - Defense World
PolyPid Announces $8.25 Million Share Sale Plan - TipRanks
PYPDPolyPid Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference - StockTitan
Craig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - MSN
PolyPid shares rise on strong Phase 3 prospects, gets buy rating - Investing.com Canada
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 - GlobeNewswire
Will PolyPid Wield The SHIELD? - RTTNews
Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd - GuruFocus.com
PolyPid Announces Publication in International Journal of - GlobeNewswire
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery - StockTitan
PolyPid retains stock target, buy rating on positive trial enrollment update By Investing.com - Investing.com South Africa
PolyPid retains stock target, buy rating on positive trial enrollment update - Investing.com India
PolyPid completes enrollment for phase 3 trial - Investing.com
PolyPid Nears Completion of Key Phase 3 Trial - TipRanks
PolyPid Announces Last Patient In for Planned Unblinded - GlobeNewswire
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - StockTitan
PolyPid to Participate in Three Upcoming Fall Investor Conferences - GlobeNewswire
Equities Analysts Offer Predictions for PolyPid Ltd.’s Q3 2024 Earnings (NASDAQ:PYPD) - Defense World
HC Wainwright Reiterates “Buy” Rating for PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: PolyPid reports a net loss of $6.3 million in the second-quarter of 2024 - Investing.com
PolyPid Reports Growth in Mid-Year Assets - TipRanks
PolyPid Advances SHIELD II Trial with Solid Financing - TipRanks
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results - GlobeNewswire
Analyzing Silk Road Medical (NASDAQ:SILK) & PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (PYPD) Scheduled to Post Earnings on Wednesday - Defense World
PolyPid secures $14 million in private placement - Investing.com
PolyPid secures $14 million in private placement By Investing.com - Investing.com UK
PolyPid Secures Funding, Extends Runway for D-PLEX100 Trial - TipRanks
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds - StockTitan
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 - GlobeNewswire
PolyPid stock hits 52-week low at $3.35 amid market challenges - Investing.com
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):